🇺🇸 FDA
Pipeline program

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”

INCB123667-203

Phase 2 other active

Quick answer

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)” for Ovarian Cancer is a Phase 2 program (other) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Incyte Biosciences Distribution B.V.
Indication
Ovarian Cancer
Phase
Phase 2
Modality
other
Status
active

Clinical trials